New pill shows promise for tough blood cancers in early trial
NCT ID NCT04139434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested an experimental oral drug called LP-108, given alone or with another drug (azacitidine), in 32 adults with blood cancers (MDS, CMML, or AML) that returned or didn't respond to prior therapy. The main goals were to find the safest dose and understand how the drug moves through the body. This is not a cure; it aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML/MDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital San Pedro de Alcántara
Cáceres, Cáceres, 10003, Spain
-
Institut Català d'oncologia - ICO Badalona
Badalona, Barcelona, 08916, Spain
-
Instituto de Investigación Sanitaria La Fe
Valencia, Valencia, CP 46026, Spain
-
MD Anderson Cancer Center
Huston, Texas, 77030, United States
-
Ohio State Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
University of Cincinnati
Cincinnati, Ohio, 45221, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat leukemias
- Can we predict psoriasis relapse after biologics? a new study digs into the clues.
- Experimental antibody drug shows promise for Hard-to-Treat lymphoma
- Engineered immune cells take aim at tough childhood leukemia
- Face shape may predict how teeth shift after braces
- Italian study tracks how venetoclax works for CLL patients in everyday practice